TransMedics Group, Inc. (NASDAQ:TMDX) Shares Sold by SG Americas Securities LLC

SG Americas Securities LLC trimmed its position in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 27.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 6,083 shares of the company’s stock after selling 2,276 shares during the period. SG Americas Securities LLC’s holdings in TransMedics Group were worth $379,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in TMDX. USA Financial Formulas acquired a new stake in TransMedics Group in the 3rd quarter valued at $55,000. Quarry LP lifted its position in shares of TransMedics Group by 557.1% during the third quarter. Quarry LP now owns 368 shares of the company’s stock worth $58,000 after purchasing an additional 312 shares during the last quarter. National Bank of Canada FI lifted its position in shares of TransMedics Group by 174.7% during the third quarter. National Bank of Canada FI now owns 412 shares of the company’s stock worth $65,000 after purchasing an additional 262 shares during the last quarter. Farther Finance Advisors LLC lifted its position in shares of TransMedics Group by 187.0% during the third quarter. Farther Finance Advisors LLC now owns 485 shares of the company’s stock worth $76,000 after purchasing an additional 316 shares during the last quarter. Finally, Rakuten Securities Inc. bought a new position in TransMedics Group in the third quarter worth about $126,000. 99.67% of the stock is currently owned by institutional investors and hedge funds.

TransMedics Group Stock Performance

Shares of TMDX opened at $68.76 on Tuesday. The company has a market capitalization of $2.31 billion, a PE ratio of 73.15 and a beta of 2.12. TransMedics Group, Inc. has a one year low of $55.00 and a one year high of $177.37. The company has a debt-to-equity ratio of 2.42, a current ratio of 8.20 and a quick ratio of 7.33. The company’s fifty day moving average price is $67.28 and its 200 day moving average price is $111.73.

Insider Transactions at TransMedics Group

In other news, insider Tamer I. Khayal sold 1,084 shares of TransMedics Group stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $86.40, for a total transaction of $93,657.60. Following the sale, the insider now directly owns 20,843 shares in the company, valued at approximately $1,800,835.20. The trade was a 4.94 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 7.00% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have issued reports on TMDX shares. Needham & Company LLC reissued a “hold” rating on shares of TransMedics Group in a report on Wednesday, December 11th. TD Cowen lowered their price objective on shares of TransMedics Group from $175.00 to $120.00 and set a “buy” rating on the stock in a research note on Monday, November 18th. JPMorgan Chase & Co. reiterated a “neutral” rating and set a $75.00 price objective (down previously from $116.00) on shares of TransMedics Group in a research note on Tuesday, December 17th. Canaccord Genuity Group reduced their target price on shares of TransMedics Group from $109.00 to $104.00 and set a “buy” rating for the company in a report on Wednesday, November 20th. Finally, Piper Sandler decreased their price objective on shares of TransMedics Group from $110.00 to $90.00 and set an “overweight” rating for the company in a research note on Wednesday, December 11th. Three analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $122.70.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.